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Background: Cardiosphere-derived cells (CDCs) exert regenerative effects in post-MI patients with LV dysfunction in the CADUCEUS trial. Here we 
report full 1-year results and correlates of efficacy.
methods: Autologous CDCs (12.5-25x106) grown from endomyocardial biopsies were infused into the infarct-related artery in 17 patients with LV 
dysfunction 1.5-3 mos post-MI (plus n=1 infused 14 mos post-MI). Eight patients were followed as routine-care controls.
results: At baseline, mean LVEF (39%) and scar size (24% of LV) did not differ between study groups. In >15 months of follow-up, safety endpoints, 
including arrhythmia, were equivalent. At 12 mos, MRI revealed relative reduction of scar size by 45% in CDC-treated subjects but not controls 
(-4.6%, p<0.01). Scar mass decreased in CDC-treated subjects (-11.9±6.8g) but not controls (-1.7±7.8g, p<0.01). Viable heart mass increased in 
CDC-treated subjects (+22.6±9.4g) but not controls (+1.8±8.7 g, p<0.001). The single subject infused compassionately 14 mos post-MI responded 
similarly. CDC therapy led to improved regional function of infarcted segments (increased strain, thickening and end-systolic thickness) compared 
to controls. Analysis of matched delayed enhancement and cine short-axis cardiac slices across timepoints revealed a correlation (r=-0.6, p<0.001) 
between scar shrinkage and improvement in regional function in CDC-treated segments, consistent with therapeutic regeneration. Covariate analysis 
revealed that baseline scar size (r=-0.89, p<0.001), and lower % of infused CD90+ cells (r=0.88, p<0.001) were associated with greater scar size 
reduction in treated patients. Scar reduction did not correlate with history of temporally remote MI, time from MI to infusion, or % of infused c-kit+ 
cells. The changes in LVEF in CDC-treated subjects (ΔLVEF=5.4±0.6% at 12 mos) were consistent with the known relationship between scar size and 
EF post-MI.
conclusions: Final 1-year results reveal that autologous CDCs are safe and effective in regenerating infarcted myocardium. Regenerative efficacy is 
unrelated to % of infused c-kit+ cells, but correlates with baseline scar size, and inversely correlates with %CD90+ cells in CDCs.
